Ligelizumab For Chronic Spontaneous Urticaria
BRITISH JOURNAL OF DERMATOLOGY（2020）
摘要
Chronic spontaneous urticaria (CSU) is a very disabling condition. It can be difficult to treat. Less than 50% of people respond to licenced dosages of H1-antihistamines (though up-dosing where safe increases the response rate). Additionally, only a small proportion respond to the addition of the leukotriene receptor antagonist (LTRA) montelukast..
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要